Prospector Partners LLC Sells 8,788 Shares of Johnson & Johnson $JNJ

Prospector Partners LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 10.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 74,542 shares of the company’s stock after selling 8,788 shares during the period. Johnson & Johnson accounts for about 1.7% of Prospector Partners LLC’s portfolio, making the stock its 21st largest position. Prospector Partners LLC’s holdings in Johnson & Johnson were worth $13,822,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the third quarter worth $26,000. Evolution Wealth Management Inc. acquired a new stake in Johnson & Johnson in the second quarter worth about $27,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson during the 3rd quarter worth about $28,000. Semmax Financial Advisors Inc. lifted its position in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. Finally, Compass Financial Services Inc grew its position in shares of Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after buying an additional 198 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Leerink Partners raised their price objective on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research note on Thursday, January 22nd. HSBC raised their price target on Johnson & Johnson from $240.00 to $265.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Wolfe Research upped their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Finally, TD Cowen upped their price target on Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $233.73.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Announced a >$1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania as part of a multi‑year U.S. manufacturing expansion — expands capacity for JNJ’s cell/biologic pipeline and signals long‑term revenue growth potential. Read More.
• Positive Sentiment: FDA approved a simplified monthly dosing schedule for RYBREVANT FASPRO (amivantamab + hyaluronidase), improving convenience for EGFR+ NSCLC patients and potentially boosting uptake and product competitiveness. Read More.
• Positive Sentiment: Received FDA Breakthrough Therapy Designation for subcutaneous amivantamab (RYBREVANT FASPRO) in advanced head & neck cancer — could speed development and improve commercial prospects if confirmatory data follow. Read More.
• Positive Sentiment: Raised the quarterly dividend to $1.30 (annualized $5.20), reinforcing the shareholder‑yield profile that supports income‑oriented ownership. Read More.
• Neutral Sentiment: Options activity around JNJ has increased, which can amplify short‑term moves; useful for traders but not a fundamental driver by itself. Read More.
• Neutral Sentiment: Small contract extension with Trellus Health keeps a patient‑support program in place — operationally positive but immaterial to overall revenue. Read More.
• Negative Sentiment: Insider selling: two executive vice presidents disclosed sizable stock sales this week (Vanessa Broadhurst sold ~6,197 shares at ~$243.39; Timothy Schmid sold ~22,623 shares at ~$244.33). Large insider sales can weigh on sentiment even if motivated by diversification or tax planning. Read More.
• Negative Sentiment: Ongoing talc litigation and recent verdict coverage keep legal risk and potential liabilities on the radar — this continues to cap valuation upside despite operational wins. Read More.

Johnson & Johnson Trading Up 0.6%

NYSE JNJ opened at $244.89 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The stock’s 50-day moving average is $219.71 and its 200-day moving average is $198.21. Johnson & Johnson has a one year low of $141.50 and a one year high of $246.35. The firm has a market cap of $590.17 billion, a P/E ratio of 22.16, a P/E/G ratio of 2.36 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion during the quarter. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.